OBR Daily Commentary

forumImage

Lilly Surges On Verzenio Survival Data In Early Breast Cancer

(PMLiVE [UK]) June 17, 2020 - New data with Eli Lilly’s CDK4/6 inhibitor Verzenio has sent the drug to the top of the class in patients with hormone receptor-positive, HER2-negative early-stage breast cancer.

Read Article arrow

Dean Gesme, MD (Posted: June 18, 2020)

quotesThe positive primary endpoint of improved iDFS with Abemaciclib plus adjuvant AI in this Monarch E interim evaluation stands in confusingly stark contrast to the negative efficacy reported from the preliminary PALLUS for adjuvant high risk early stage breast cancer! Could this be due to genuine differences in efficacy, differences in the study populations, or just statistical flukes in the data?quotes

Add Comment 1 Comment
forumImage

Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

(Pfizer) May 29, 2020 - As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. reports that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee (DMC) of the collaborative Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS). Patients currently receiving palbociclib in the study will be advised about next steps by their physicians and long-term follow up of all patients will proceed as planned. No unexpected new safety signals were observed in patients receiving palbociclib.

Read Article arrow

Dean Gesme (Posted: May 30, 2020)

quotesDisappointing that adding palbociclib to Standard adjuvant aromatase inhibitor therapy for Stage II & III hormone receptor positive breast cancer failed to improve overall outcomes in this study. Adjuvant studies with ribociclib and abemociclib are awaited but this outcome from PALLAS dampens the prospects for major clinical benefits.quotes

Add Comment 1 Comment
forumImage

GRAIL Announces Validation of its Multi-Cancer Early Detection Test Published in Annals of Oncology

(GRAIL) Mar 30, 2020 - Circulating Cell-free Genome Atlas (CCGA) results demonstrate robust validity of GRAIL’s multi-cancer early detection approach.

Read Article arrow

Dean Gesme, MD (Posted: April 01, 2020)

quotesThe reported low false positive rate in this large validation data set and high diagnostic acumen for the cancer primary sites rpresents an extremely promising first step. The vital next step is to determine the false negative rates and whether this technology can allow early enough detection of malignancies to afford significant outcomes benefits in real world data sets.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...